GT Biopharma, Inc. (GTBP) › Total LiabilitiesGT Biopharma, Inc. (GTBP) — Total LiabilitiesAnnual figures by period end, from SEC filings.2010-12-31: $5.65M2011-12-31: $5.23M2012-12-31: $6.56M2013-12-31: $6.48M2014-12-31: $30.46M2015-12-31: $50.62M2016-12-31: $18.95M2017-12-31: $2.68M2018-12-31: $14.03M2019-12-31: $19.71M2021-12-31: $10.26M2022-12-31: $5.00M2023-12-31: $6.63M2025-06-30: $31.04M2025-09-30: $1.32M$1.32M2010-12-31Total Liabilities (USD)2025-09-30Period endedTotal LiabilitiesChange YoYSource filing2025-09-30$1.32M—2026-03-02Balance as of period end2025-06-30$31.04M—2026-03-02Balance as of period end2023-12-31$6.63M+32.6%2024-03-26Balance as of period end2022-12-31$5.00M-51.2%2024-03-26Balance as of period end2021-12-31$10.26M—2023-03-30Balance as of period end2019-12-31$19.71M+40.5%2020-03-27Balance as of period end2018-12-31$14.03M+423.7%2020-03-27Balance as of period end2017-12-31$2.68M-85.9%2019-03-29Balance as of period end2016-12-31$18.95M-62.6%2018-03-01Balance as of period end2015-12-31$50.62M+66.2%2018-02-28Balance as of period end2014-12-31$30.46M+370.0%2018-02-28Balance as of period end2013-12-31$6.48M-1.2%2015-03-31Balance as of period end2012-12-31$6.56M+25.5%2015-01-08Balance as of period end2011-12-31$5.23M-7.5%2012-04-16Balance as of period end2010-12-31$5.65M—2012-04-16Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)